Polycythemia vera (PV) is a relatively indolent myeloid neoplasm with median survival that
exceeds 35 years in young patients, but its natural history might be interrupted by …

Polycythaemia vera is associated with a reduced quality of life, a high rate of vascular
events, and an intrinsic risk of disease evolution. The results of several randomised trials for …

Abstract Disease Overview Polycythemia vera (PV) is a JAK2‐mutated myeloproliferative
neoplasm characterized by clonal erythrocytosis; other features include leukocytosis …

A group of international experts, including hematopathologists, oncologists, and geneticists
were recently summoned (September 2021, Chicago, IL, USA) to update the 2016/17 World …

Abstract BCR:: ABL1-negative myeloproliferative neoplasms (MPNs) are clonal diseases
originating from a single hematopoietic stem cell that cause excessive production of mature …

Current recommended risk scores to predict thrombotic events associated with
myeloproliferative neoplasms (MPN) do not discriminate between arterial and venous …

Polycythemia vera (PV) belongs to the BCR-ABL1–negative myeloproliferative neoplasms
and is characterized by activating mutations in JAK2 and clinically presents with …

Ropeginterferon alfa-2b is a novel, long-acting mono-pegylated proline-IFN-alpha-2b
approved for treatment of polycythemia vera in adults, regardless of thrombotic risk level or …

A state‐of‐the‐art lecture titled “Myeloproliferative Neoplasm‐associated Thrombosis” was
presented at the ISTH congress in 2021. We summarize here the main points of the lecture …

Interferon-based therapies, such as ropeginterferon alfa-2b have emerged as promising
disease-modifying agents for myeloproliferative neoplasms (MPNs), including essential …